title: Inhibition of tumor angiogenesis by globotriaosylceramide immunotargeting.
abstract: Current antiangiogenic immunotherapeutic strategies mainly focus on the blockade of circulating cytokines or receptors that are overexpressed by endothelial cells. We proposed globotriaosylceramide (Gb3) as a viable alternative target for antiangiogenic therapies. In this setting, we developed an anti-Gb3 antibody and validated its therapeutic efficacy in metastatic tumor models.
authors.affiliation: Inserm; UMR892; Nantes, France ; Université de Nantes; UFR des Sciences Pharmaceutiques et Biologiques; Nantes, France ; CNRS; UMR 6299; Nantes, France.
authors.forename: Stéphane
authors.initials: S
authors.lastname: Birklé
authors.forename: Ariane
authors.initials: A
authors.lastname: Desselle
authors.forename: Tanguy
authors.initials: T
authors.lastname: Chaumette
authors.forename: Marie-Hélène
authors.initials: MH
authors.lastname: Gaugler
authors.forename: Denis
authors.initials: D
authors.lastname: Cochonneau
authors.forename: Julien
authors.initials: J
authors.lastname: Fleurence
authors.forename: Nolwenn
authors.initials: N
authors.lastname: Dubois
authors.forename: Philippe
authors.initials: P
authors.lastname: Hulin
authors.forename: Jacques
authors.initials: J
authors.lastname: Aubry
authors.forename: François
authors.initials: F
authors.lastname: Paris
keywords: Gb3; antiangiogenic therapy; antibody; glycosphingolipid